When should FDG‐PET be used in the modern management of lymphoma?
- 17 October 2013
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 164 (3), 315-328
- https://doi.org/10.1111/bjh.12601
Abstract
Positron Emission Tomography (PET) is a functional imaging technique that, combined with computerized tomography (PET-CT), is increasingly used in lymphoma. Most subtypes accumulate fluorodeoxyglucose (FDG) and the increased sensitivity of PET-CT, especially for extranodal disease, compared to CT, makes PET-CT an attractive staging tool. The availability of a staging PET-CT scan also improves the accuracy of subsequent response assessment. 'Interim' PET-CT can be used to assess early response and end-of-treatment PET-CT assesses remission. Clinical trials are currently seeking to establish whether the predictive value of PET-CT can be successfully used to guide individual treatment to reduce toxicity and/or to improve outcomes. Standardized methods for performing and reporting PET have been developed in the context of trials. The role of PET in transplantation selection is currently evolving, as it appears to be more accurate and prognostic than CT. The role of FDG PET-CT throughout the management course in patients with lymphoma is explored in this review, with areas discussed that may limit the use of PET-CT imaging which clinicians should be familiar with to inform practice.Keywords
This publication has 95 references indexed in Scilit:
- In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with 18F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Does BiopsyJournal of Nuclear Medicine, 2013
- International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among ReviewersJournal of Nuclear Medicine, 2013
- Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab eraAmerican Journal of Hematology, 2013
- 18F-fluorodeoxyglucose–positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS groupAnnals Of Oncology, 2011
- End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphomaAnnals Of Oncology, 2010
- Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphomaAnnals Of Oncology, 2010
- Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2009
- The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvementEuropean Journal of Haematology, 2006
- Limitations of PET for imaging lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003